-
2
-
-
0026174552
-
Characterization of an antip185her2 monoclonal antibody that stimulates receptor function and inhibits tumor cell growth
-
Sarup JC, Johnson RM, King KL, Fendly BM, Lipari MT, Napier MA, Ullrich A, Shepard HM (1991) Characterization of an antip185HER2 monoclonal antibody that stimulates receptor function and inhibits tumor cell growth. Growth Regul 1:72-82
-
(1991)
Growth Regul
, vol.1
, pp. 72-82
-
-
Sarup, J.C.1
Johnson, R.M.2
King, K.L.3
Fendly, B.M.4
Lipari, M.T.5
Napier, M.A.6
Ullrich, A.7
Shepard, H.M.8
-
3
-
-
0037099532
-
Herceptin-induced inhibition of phosphatidylinositol-3 kinase and akt is required for antibody-mediated evects on p27, cyclin d1, and antitumor action
-
Yakes FM, Chinratanalab W, Ritter CA, King W, Seelig S, Arteaga CL (2002) Herceptin-induced inhibition of phosphatidylinositol-3 kinase and Akt Is required for antibody-mediated eVects on p27, cyclin D1, and antitumor action. Cancer Res 62:4132-4141
-
(2002)
Cancer Res
, vol.62
, pp. 4132-4141
-
-
Yakes, F.M.1
Chinratanalab, W.2
Ritter, C.A.3
King, W.4
Seelig, S.5
Arteaga, C.L.6
-
4
-
-
4444372733
-
Pilot study of the mechanism of action of preoperative trastuzumab in patients with primary operable breast tumors overexpressing her2
-
Gennari R, Menard S, Fagnoni F, Ponchio L, Scelsi M, Tagliabue E, Castiglioni F, Villani L, Magalotti C, Gibelli N, Oliviero B, Ballardini B, Da Prada G, Zambelli A, Costa A (2004) Pilot study of the mechanism of action of preoperative trastuzumab in patients with primary operable breast tumors overexpressing HER2. Clin Cancer Res 10:5650-5655
-
(2004)
Clin Cancer Res
, vol.10
, pp. 5650-5655
-
-
Gennari, R.1
Menard, S.2
Fagnoni, F.3
Ponchio, L.4
Scelsi, M.5
Tagliabue, E.6
Castiglioni, F.7
Villani, L.8
Magalotti, C.9
Gibelli, N.10
Oliviero, B.11
Ballardini, B.12
Da Prada, G.13
Zambelli, A.14
Costa, A.15
-
5
-
-
0032885461
-
Natural killer cell cytotoxicity of breast cancer targets is enhanced by two distinct mechanisms of antibody-dependent cellular cytotoxicity against lfa-3 and her2/neu
-
Cooley S, Burns LJ, Repka T, Miller JS (1999) Natural killer cell cytotoxicity of breast cancer targets is enhanced by two distinct mechanisms of antibody-dependent cellular cytotoxicity against LFA-3 and HER2/neu. Exp Hematol 27:1533-1541
-
(1999)
Exp Hematol
, vol.27
, pp. 1533-1541
-
-
Cooley, S.1
Burns, L.J.2
Repka, T.3
Miller, J.S.4
-
6
-
-
0034076307
-
Inhibitory fc receptors modulate in vivo cytotoxicity against tumor targets
-
Clynes RA, Towers TL, Presta LG, Ravetch JV (2000) Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets. Nat Med 6:443-446
-
(2000)
Nat Med
, vol.6
, pp. 443-446
-
-
Clynes, R.A.1
Towers, T.L.2
Presta, L.G.3
Ravetch, J.V.4
-
7
-
-
0027375130
-
Diverential responses of human tumor cell lines to anti-p185her2 monoclonal antibodies
-
Lewis GD, Figari I, Fendly B, Wong WL, Carter P, Gorman C, Shepard HM (1993) DiVerential responses of human tumor cell lines to anti-p185HER2 monoclonal antibodies. Cancer Immunol Immunother 37:255-263
-
(1993)
Cancer Immunol Immunother
, vol.37
, pp. 255-263
-
-
Lewis, G.D.1
Figari, I.2
Fendly, B.3
Wong, W.L.4
Carter, P.5
Gorman, C.6
Shepard, H.M.7
-
8
-
-
0035869407
-
Use of chemotherapy plus a monoclonal antibody against her2 for metastatic breast cancer that overexpresses her2
-
Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, Fleming T, Eiermann W, Wolter J, Pegram M, Baselga J, Norton L (2001) Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 344:783-792
-
(2001)
N Engl J Med
, vol.344
, pp. 783-792
-
-
Slamon, D.J.1
Leyland-Jones, B.2
Shak, S.3
Fuchs, H.4
Paton, V.5
Bajamonde, A.6
Fleming, T.7
Eiermann, W.8
Wolter, J.9
Pegram, M.10
Baselga, J.11
Norton, L.12
-
9
-
-
0032850677
-
Multinational study of the eycacy and safety of humanized anti-her2 monoclonal antibody in women who have her2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease
-
Cobleigh MA, Vogel CL, Tripathy D, Robert NJ, Scholl S, Fehrenbacher L, Wolter JM, Paton V, Shak S, Lieberman G, Slamon DJ (1999) Multinational study of the eYcacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J Clin Oncol 17:2639-2648
-
(1999)
J Clin Oncol
, vol.17
, pp. 2639-2648
-
-
Cobleigh, M.A.1
Vogel, C.L.2
Tripathy, D.3
Robert, N.J.4
Scholl, S.5
Fehrenbacher, L.6
Wolter, J.M.7
Paton, V.8
Shak, S.9
Lieberman, G.10
Slamon, D.J.11
-
10
-
-
77956262693
-
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of her2-positive advanced gastric or gastrooesophageal junction cancer (toga): A phase 3, open-label, randomised controlled trial
-
Bang YJ, Van Cutsem E, Feyereislova A, Chung HC, Shen L, Sawaki A, Lordick F, Ohtsu A, Omuro Y, Satoh T, Aprile G, Kulikov E, Hill J, Lehle M, RuschoV J, Kang YK (2010) Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastrooesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet 376:687-697
-
(2010)
Lancet
, vol.376
, pp. 687-697
-
-
Bang, Y.J.1
Van Cutsem, E.2
Feyereislova, A.3
Chung, H.C.4
Shen, L.5
Sawaki, A.6
Lordick, F.7
Ohtsu, A.8
Omuro, Y.9
Satoh, T.10
Aprile, G.11
Kulikov, E.12
Hill, J.13
Lehle, M.14
RuschoV, J.15
Kang, Y.K.16
-
11
-
-
0024337144
-
Studies of the her-2/neu proto-oncogene in human breast and ovarian cancer
-
Slamon DJ, Godolphin W, Jones LA, Holt JA, Wong SG, Keith DE, Levin WJ, Stuart SG, Udove J, Ullrich A et al (1989) Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 244:707-712
-
(1989)
Science
, vol.244
, pp. 707-712
-
-
Slamon, D.J.1
Godolphin, W.2
Jones, L.A.3
Holt, J.A.4
Wong, S.G.5
Keith, D.E.6
Levin, W.J.7
Stuart, S.G.8
Udove, J.9
Ullrich, A.10
-
12
-
-
50849123421
-
Her2 in gastric cancer: A new prognostic factor and a novel therapeutic target
-
Gravalos C, Jimeno A (2008) HER2 in gastric cancer: a new prognostic factor and a novel therapeutic target. Ann Oncol 19:1523-1529
-
(2008)
Ann Oncol
, vol.19
, pp. 1523-1529
-
-
Gravalos, C.1
Jimeno, A.2
-
13
-
-
20044372721
-
Ampliwcation of her-2 in gastric carcinoma: Association with topoisomerase iialpha gene ampliwcation, intestinal type, poor prognosis and sensitivity to trastuzumab
-
Tanner M, Hollmen M, Junttila TT, Kapanen AI, Tommola S, Soini Y, Helin H, Salo J, Joensuu H, Sihvo E, Elenius K, Isola J (2005) AmpliWcation of HER-2 in gastric carcinoma: association with topoisomerase IIalpha gene ampliWcation, intestinal type, poor prognosis and sensitivity to trastuzumab. Ann Oncol 16:273-278
-
(2005)
Ann Oncol
, vol.16
, pp. 273-278
-
-
Tanner, M.1
Hollmen, M.2
Junttila, T.T.3
Kapanen, A.I.4
Tommola, S.5
Soini, Y.6
Helin, H.7
Salo, J.8
Joensuu, H.9
Sihvo, E.10
Elenius, K.11
Isola, J.12
-
14
-
-
0036467826
-
Eycacy and safety of trastuzumab as a single agent in wrst-line treatment of her2-overexpressing metastatic breast cancer
-
Vogel CL, Cobleigh MA, Tripathy D, Gutheil JC, Harris LN, Fehrenbacher L, Slamon DJ, Murphy M, Novotny WF, Burchmore M, Shak S, Stewart SJ, Press M (2002) EYcacy and safety of trastuzumab as a single agent in Wrst-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol 20:719-726
-
(2002)
J Clin Oncol
, vol.20
, pp. 719-726
-
-
Vogel, C.L.1
Cobleigh, M.A.2
Tripathy, D.3
Gutheil, J.C.4
Harris, L.N.5
Fehrenbacher, L.6
Slamon, D.J.7
Murphy, M.8
Novotny, W.F.9
Burchmore, M.10
Shak, S.11
Stewart, S.J.12
Press, M.13
-
15
-
-
73349085919
-
Understanding the mechanisms behind trastuzumab therapy for human epidermal growth factor receptor 2-positive breast cancer
-
Spector NL, Blackwell KL (2009) Understanding the mechanisms behind trastuzumab therapy for human epidermal growth factor receptor 2-positive breast cancer. J Clin Oncol 27:5838-5847
-
(2009)
J Clin Oncol
, vol.27
, pp. 5838-5847
-
-
Spector, N.L.1
Blackwell, K.L.2
-
16
-
-
34247588567
-
Expression of p95her2, a truncated form of the her2 receptor, and response to anti-her2 therapies in breast cancer
-
Scaltriti M, Rojo F, Ocana A, Anido J, Guzman M, Cortes J, Di Cosimo S, Matias-Guiu X, Ramon y Cajal S, Arribas J, Baselga J (2007) Expression of p95HER2, a truncated form of the HER2 receptor, and response to anti-HER2 therapies in breast cancer. J Natl Cancer Inst 99:628-638
-
(2007)
J Natl Cancer Inst
, vol.99
, pp. 628-638
-
-
Scaltriti, M.1
Rojo, F.2
Ocana, A.3
Anido, J.4
Guzman, M.5
Cortes, J.6
Di Cosimo, S.7
Matias-Guiu, X.8
Ramon Cajal, S.9
Arribas, J.10
Baselga, J.11
-
17
-
-
0036187710
-
Nh(2)-Terminal truncated her-2 protein but not full-length receptor is associated with nodal metastasis in human breast cancer
-
Molina MA, Saez R, Ramsey EE, Garcia-Barchino MJ, Rojo F, Evans AJ, Albanell J, Keenan EJ, Lluch A, Garcia-Conde J, Baselga J, Clinton GM (2002) NH(2)-Terminal truncated HER-2 protein but not full-length receptor is associated with nodal metastasis in human breast cancer. Clin Cancer Res 8:347-353
-
(2002)
Clin Cancer Res
, vol.8
, pp. 347-353
-
-
Molina, M.A.1
Saez, R.2
Ramsey, E.E.3
Garcia-Barchino, M.J.4
Rojo, F.5
Evans, A.J.6
Albanell, J.7
Keenan, E.J.8
Lluch, A.9
Garcia-Conde, J.10
Baselga, J.11
Clinton, G.M.12
-
18
-
-
33846552656
-
Escape from her-family tyrosine kinase inhibitor therapy by the kinase-inactive her3
-
Sergina NV, Rausch M, Wang D, Blair J, Hann B, Shokat KM, Moasser MM (2007) Escape from HER-family tyrosine kinase inhibitor therapy by the kinase-inactive HER3. Nature 445:437-441
-
(2007)
Nature
, vol.445
, pp. 437-441
-
-
Sergina, N.V.1
Rausch, M.2
Wang, D.3
Blair, J.4
Hann, B.5
Shokat, K.M.6
Moasser, M.M.7
-
19
-
-
0346154748
-
Molecular mechanisms underlying igf-i-induced attenuation of the growth-inhibitory activity of trastuzumab (herceptin) on skbr3 breast cancer cells
-
Lu Y, Zi X, Pollak M (2004) Molecular mechanisms underlying IGF-I-induced attenuation of the growth-inhibitory activity of trastuzumab (Herceptin) on SKBR3 breast cancer cells. Int J Cancer 108:334-341
-
(2004)
Int J Cancer
, vol.108
, pp. 334-341
-
-
Lu, Y.1
Zi, X.2
Pollak, M.3
-
20
-
-
28244432561
-
Insulin-like growth factor-i receptor/human epidermal growth factor receptor 2 heterodimerization contributes to trastuzumab resistance of breast cancer cells
-
Nahta R, Yuan LX, Zhang B, Kobayashi R, Esteva FJ (2005) Insulin-like growth factor-I receptor/human epidermal growth factor receptor 2 heterodimerization contributes to trastuzumab resistance of breast cancer cells. Cancer Res 65:11118-11128
-
(2005)
Cancer Res
, vol.65
, pp. 11118-11128
-
-
Nahta, R.1
Yuan, L.X.2
Zhang, B.3
Kobayashi, R.4
Esteva, F.J.5
-
21
-
-
5144226211
-
Pten activation contributes to tumor inhibition by trastuzumab, and loss of pten predicts trastuzumab resistance in patients
-
Nagata Y, Lan KH, Zhou X, Tan M, Esteva FJ, Sahin AA, Klos KS, Li P, Monia BP, Nguyen NT, Hortobagyi GN, Hung MC, Yu D (2004) PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients. Cancer Cell 6:117-127
-
(2004)
Cancer Cell
, vol.6
, pp. 117-127
-
-
Nagata, Y.1
Lan, K.H.2
Zhou, X.3
Tan, M.4
Esteva, F.J.5
Sahin, A.A.6
Klos, K.S.7
Li, P.8
Monia, B.P.9
Nguyen, N.T.10
Hortobagyi, G.N.11
Hung, M.C.12
Yu, D.13
-
22
-
-
0034920457
-
Loss of expression of the pten gene protein product is associated with poor outcome in breast cancer
-
Depowski PL, Rosenthal SI, Ross JS (2001) Loss of expression of the PTEN gene protein product is associated with poor outcome in breast cancer. Mod Pathol 14:672-676
-
(2001)
Mod Pathol
, vol.14
, pp. 672-676
-
-
Depowski, P.L.1
Rosenthal, S.I.2
Ross, J.S.3
-
23
-
-
9244219598
-
Breast cancer -loss of pten predicts resistance to treatment
-
PandolW PP (2004) Breast cancer -loss of PTEN predicts resistance to treatment. N Engl J Med 351:2337-2338
-
(2004)
N Engl J Med
, vol.351
, pp. 2337-2338
-
-
PandolW, P.P.1
-
24
-
-
44949125431
-
Correlation between nk function and response to trastuzumab in metastatic breast cancer patients
-
Beano A, Signorino E, Evangelista A, Brusa D, Mistrangelo M, Polimeni MA, Spadi R, Donadio M, CiuVreda L, Matera L (2008) Correlation between NK function and response to trastuzumab in metastatic breast cancer patients. J Transl Med 6:25
-
(2008)
J Transl Med
, vol.6
, pp. 25
-
-
Beano, A.1
Signorino, E.2
Evangelista, A.3
Brusa, D.4
Mistrangelo, M.5
Polimeni, M.A.6
Spadi, R.7
Donadio, M.8
CiuVreda, L.9
Matera, L.10
-
25
-
-
77953678688
-
Understanding and circumventing resistance to anticancer monoclonal antibodies
-
Reslan L, Dalle S, Dumontet C (2009) Understanding and circumventing resistance to anticancer monoclonal antibodies. MAbs 1:222-229
-
(2009)
MAbs
, vol.1
, pp. 222-229
-
-
Reslan, L.1
Dalle, S.2
Dumontet, C.3
-
26
-
-
18344390418
-
Erbb receptors and cancer: The complexity of targeted inhibitors
-
Hynes NE, Lane HA (2005) ERBB receptors and cancer: the complexity of targeted inhibitors. Nat Rev Cancer 5:341-354
-
(2005)
Nat Rev Cancer
, vol.5
, pp. 341-354
-
-
Hynes, N.E.1
Lane, H.A.2
-
27
-
-
0025883759
-
Oncogenic potential of erbb-2 in human mammary epithelial cells
-
Pierce JH, Arnstein P, DiMarco E, Artrip J, Kraus MH, Lonardo F, Di Fiore PP, Aaronson SA (1991) Oncogenic potential of erbB-2 in human mammary epithelial cells. Oncogene 6:1189-1194
-
(1991)
Oncogene
, vol.6
, pp. 1189-1194
-
-
Pierce, J.H.1
Arnstein, P.2
DiMarco, E.3
Artrip, J.4
Kraus, M.H.5
Lonardo, F.6
Di Fiore, P.P.7
Aaronson, S.A.8
-
28
-
-
0029162564
-
Heregulin-dependent regulation of her2/neu oncogenic signaling by heterodimerization with her3
-
Wallasch C, Weiss FU, Niederfellner G, Jallal B, Issing W, Ullrich A (1995) Heregulin-dependent regulation of HER2/neu oncogenic signaling by heterodimerization with HER3. EMBO J 14:4267-4275
-
(1995)
EMBO J
, vol.14
, pp. 4267-4275
-
-
Wallasch, C.1
Weiss, F.U.2
Niederfellner, G.3
Jallal, B.4
Issing, W.5
Ullrich, A.6
-
29
-
-
2142843806
-
Diversiwcation of neu diverentiation factor and epidermal growth factor signaling by combinatorial receptor interactions
-
Pinkas-Kramarski R, Soussan L, Waterman H, Levkowitz G, Alroy I, Klapper L, Lavi S, Seger R, Ratzkin BJ, Sela M, Yarden Y (1996) DiversiWcation of Neu diVerentiation factor and epidermal growth factor signaling by combinatorial receptor interactions. EMBO J 15:2452-2467
-
(1996)
EMBO J
, vol.15
, pp. 2452-2467
-
-
Pinkas-Kramarski, R.1
Soussan, L.2
Waterman, H.3
Levkowitz, G.4
Alroy, I.5
Klapper, L.6
Lavi, S.7
Seger, R.8
Ratzkin, B.J.9
Sela, M.10
Yarden, Y.11
-
30
-
-
9444252957
-
Endocytosis and sorting of erbb2 and the site of action of cancer therapeutics trastuzumab and geldanamycin
-
Austin CD, De Maziere AM, Pisacane PI, van Dijk SM, Eigenbrot C, Sliwkowski MX, Klumperman J, Scheller RH (2004) Endocytosis and sorting of ErbB2 and the site of action of cancer therapeutics trastuzumab and geldanamycin. Mol Biol Cell 15:5268-5282
-
(2004)
Mol Biol Cell
, vol.15
, pp. 5268-5282
-
-
Austin, C.D.1
De Maziere, A.M.2
Pisacane, P.I.3
Van Dijk, S.M.4
Eigenbrot, C.5
Sliwkowski, M.X.6
Klumperman, J.7
Scheller, R.H.8
-
31
-
-
1642422374
-
Association with membrane protrusions makes erbb2 an internalization- resistant receptor
-
Hommelgaard AM, Lerdrup M, van Deurs B (2004) Association with membrane protrusions makes ErbB2 an internalization-resistant receptor. Mol Biol Cell 15:1557-1567
-
(2004)
Mol Biol Cell
, vol.15
, pp. 1557-1567
-
-
Hommelgaard, A.M.1
Lerdrup, M.2
Van Deurs, B.3
-
32
-
-
27244450053
-
Trastuzumab-mediated antibody-dependent cellular cytotoxicity against esophageal squamous cell carcinoma
-
Mimura K, Kono K, Hanawa M, Kanzaki M, Nakao A, Ooi A, Fujii H (2005) Trastuzumab-mediated antibody-dependent cellular cytotoxicity against esophageal squamous cell carcinoma. Clin Cancer Res 11:4898-4904
-
(2005)
Clin Cancer Res
, vol.11
, pp. 4898-4904
-
-
Mimura, K.1
Kono, K.2
Hanawa, M.3
Kanzaki, M.4
Nakao, A.5
Ooi, A.6
Fujii, H.7
-
33
-
-
37049183697
-
Human breast cancer: Correlation of relapse and survival with ampliwcation of the her-2/neu oncogene
-
Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL (1987) Human breast cancer: correlation of relapse and survival with ampliWcation of the HER-2/neu oncogene. Science 235:177-182
-
(1987)
Science
, vol.235
, pp. 177-182
-
-
Slamon, D.J.1
Clark, G.M.2
Wong, S.G.3
Levin, W.J.4
Ullrich, A.5
McGuire, W.L.6
-
34
-
-
0023857935
-
Correlation of c-erbb-2 gene ampliwcation and protein expression in human breast carcinoma with nodal status and nuclear grading
-
Berger MS, Locher GW, Saurer S, Gullick WJ, WaterWeld MD, Groner B, Hynes NE (1988) Correlation of c-erbB-2 gene ampliWcation and protein expression in human breast carcinoma with nodal status and nuclear grading. Cancer Res 48:1238-1243
-
(1988)
Cancer Res
, vol.48
, pp. 1238-1243
-
-
Berger, M.S.1
Locher, G.W.2
Saurer, S.3
Gullick, W.J.4
WaterWeld, M.D.5
Groner, B.6
Hynes, N.E.7
-
35
-
-
65349101151
-
Ligand-independent her2/her3/pi3k complex is disrupted by trastuzumab and is evectively inhibited by the pi3k inhibitor gdc-0941
-
Junttila TT, Akita RW, Parsons K, Fields C, Lewis Phillips GD, Friedman LS, Sampath D, Sliwkowski MX (2009) Ligand-independent HER2/HER3/PI3K complex is disrupted by trastuzumab and is eVectively inhibited by the PI3K inhibitor GDC-0941. Cancer Cell 15:429-440
-
(2009)
Cancer Cell
, vol.15
, pp. 429-440
-
-
Junttila, T.T.1
Akita, R.W.2
Parsons, K.3
Fields, C.4
Lewis Phillips, G.D.5
Friedman, L.S.6
Sampath, D.7
Sliwkowski, M.X.8
-
36
-
-
48649092620
-
A central role for her3 in her2-Ampliwed breast cancer: Implications for targeted therapy
-
Lee-HoeXich ST, Crocker L, Yao E, Pham T, Munroe X, HoeXich KP, Sliwkowski MX, Stern HM (2008) A central role for HER3 in HER2-AmpliWed breast cancer: implications for targeted therapy. Cancer Res 68:5878-5887
-
(2008)
Cancer Res
, vol.68
, pp. 5878-5887
-
-
Lee-HoeXich, S.T.1
Crocker, L.2
Yao, E.3
Pham, T.4
Munroe, X.5
HoeXich, K.P.6
Sliwkowski, M.X.7
Stern, H.M.8
-
37
-
-
0037142184
-
Rat muc4 (sialomucin complex) reduces binding of anti-erbb2 antibodies to tumor cell surfaces, a potential mechanism for herceptin resistance
-
Price-Schiavi SA, Jepson S, Li P, Arango M, Rudland PS, Yee L, Carraway KL (2002) Rat Muc4 (sialomucin complex) reduces binding of anti-ErbB2 antibodies to tumor cell surfaces, a potential mechanism for herceptin resistance. Int J Cancer 99:783-791
-
(2002)
Int J Cancer
, vol.99
, pp. 783-791
-
-
Price-Schiavi, S.A.1
Jepson, S.2
Li, P.3
Arango, M.4
Rudland, P.S.5
Yee, L.6
Carraway, K.L.7
-
38
-
-
12544250996
-
Decreased accessibility and lack of activation of erbb2 in jimt-1, a herceptin-resistant, muc4-expressing breast cancer cell line
-
Nagy P, Friedlander E, Tanner M, Kapanen AI, Carraway KL, Isola J, Jovin TM (2005) Decreased accessibility and lack of activation of ErbB2 in JIMT-1, a herceptin-resistant, MUC4-expressing breast cancer cell line. Cancer Res 65:473-482
-
(2005)
Cancer Res
, vol.65
, pp. 473-482
-
-
Nagy, P.1
Friedlander, E.2
Tanner, M.3
Kapanen, A.I.4
Carraway, K.L.5
Isola, J.6
Jovin, T.M.7
-
39
-
-
44249092320
-
Assessment of a her2 scoring system for gastric cancer: Results from a validation study
-
Hofmann M, Stoss O, Shi D, Buttner R, van de Vijver M, Kim W, Ochiai A, RuschoV J, Henkel T (2008) Assessment of a HER2 scoring system for gastric cancer: results from a validation study. Histopathology 52:797-805
-
(2008)
Histopathology
, vol.52
, pp. 797-805
-
-
Hofmann, M.1
Stoss, O.2
Shi, D.3
Buttner, R.4
Van De Vijver, M.5
Kim, W.6
Ochiai, A.7
RuschoV, J.8
Henkel, T.9
-
40
-
-
3042521542
-
Cellular dynamics visualized in live cells in vitro and in vivo by diverential dual-color nuclear-cytoplasmic xuorescent-protein expression
-
Yamamoto N, Jiang P, Yang M, Xu M, Yamauchi K, Tsuchiya H, Tomita K, Wahl GM, Moossa AR, HoVman RM (2004) Cellular dynamics visualized in live cells in vitro and in vivo by diVerential dual-color nuclear-cytoplasmic Xuorescent-protein expression. Cancer Res 64:4251-4256
-
(2004)
Cancer Res
, vol.64
, pp. 4251-4256
-
-
Yamamoto, N.1
Jiang, P.2
Yang, M.3
Xu, M.4
Yamauchi, K.5
Tsuchiya, H.6
Tomita, K.7
Wahl, G.M.8
Moossa, A.R.9
HoVman, R.M.10
-
41
-
-
25844461626
-
The multiple uses of xuorescent proteins to visualize cancer in vivo
-
HoVman RM (2005) The multiple uses of Xuorescent proteins to visualize cancer in vivo. Nat Rev Cancer 5:796-806
-
(2005)
Nat Rev Cancer
, vol.5
, pp. 796-806
-
-
HoVman, R.M.1
-
42
-
-
0030844812
-
Suppressed cellmediated immunity and monocyte and natural killer cell activity following allogeneic immunization of women with spontaneous recurrent abortion
-
Gafter U, Sredni B, Segal J, Kalechman Y (1997) Suppressed cellmediated immunity and monocyte and natural killer cell activity following allogeneic immunization of women with spontaneous recurrent abortion. J Clin Immunol 17:408-419
-
(1997)
J Clin Immunol
, vol.17
, pp. 408-419
-
-
Gafter, U.1
Sredni, B.2
Segal, J.3
Kalechman, Y.4
-
43
-
-
0037108686
-
Impaired antibody-dependent cellular cytotoxicity mediated by herceptin in patients with gastric cancer
-
Kono K, Takahashi A, Ichihara F, Sugai H, Fujii H, Matsumoto Y (2002) Impaired antibody-dependent cellular cytotoxicity mediated by herceptin in patients with gastric cancer. Cancer Res 62:5813-5817
-
(2002)
Cancer Res
, vol.62
, pp. 5813-5817
-
-
Kono, K.1
Takahashi, A.2
Ichihara, F.3
Sugai, H.4
Fujii, H.5
Matsumoto, Y.6
-
44
-
-
1642566826
-
Tumor-inwltrating lymphocyte secretion of il-6 antagonizes tumor-derived tgfbeta 1 and restores the lymphokine-Activated killing activity
-
Hsiao YW, Liao KW, Hung SW, Chu RM (2004) Tumor-inWltrating lymphocyte secretion of IL-6 antagonizes tumor-derived TGFbeta 1 and restores the lymphokine-Activated killing activity. J Immunol 172:1508-1514
-
(2004)
J Immunol
, vol.172
, pp. 1508-1514
-
-
Hsiao, Y.W.1
Liao, K.W.2
Hung, S.W.3
Chu, R.M.4
-
45
-
-
0028116922
-
The lack of nk cytotoxicity associated with fresh hucb may be due to the presence of soluble hla in the serum
-
Webb BJ, Bochan MR, Montel A, Padilla LM, Brahmi Z (1994) The lack of NK cytotoxicity associated with fresh HUCB may be due to the presence of soluble HLA in the serum. Cell Immunol 159:246-261
-
(1994)
Cell Immunol
, vol.159
, pp. 246-261
-
-
Webb, B.J.1
Bochan, M.R.2
Montel, A.3
Padilla, L.M.4
Brahmi, Z.5
-
46
-
-
0033367649
-
Interleukin-10 reduces natural killer (nk) sensitivity of tumor cells by downregulating nk target structure expression
-
Tsuruma T, Yagihashi A, Hirata K, Torigoe T, Araya J, Watanabe N, Sato N (1999) Interleukin-10 reduces natural killer (NK) sensitivity of tumor cells by downregulating NK target structure expression. Cell Immunol 198:103-110
-
(1999)
Cell Immunol
, vol.198
, pp. 103-110
-
-
Tsuruma, T.1
Yagihashi, A.2
Hirata, K.3
Torigoe, T.4
Araya, J.5
Watanabe, N.6
Sato, N.7
|